Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| entinostat | HDAC1 | Direct | 2 | ||||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study | HDAC1 | Direct | 2 | ||||||||
| pembrolizumab, guadecitabine, mocetinostat | HDAC1 | Direct | 2 | ||||||||
| pharmacological study, romidepsin | HDAC1 | Direct | 2 | ||||||||
| 3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat | HDAC1 | Direct | 1 | ||||||||
| 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat | HDAC1 | Direct | 1 | ||||||||
| adjuvant therapy, temozolomide, valproic acid, radiation therapy | HDAC1 | Direct | 1 | ||||||||
| adriamycin, cyclophosphamide, vindesine, valproic acid | HDAC1 | Direct | 1 | ||||||||
| arsenic trioxide | HDAC1 | Direct | 1 | ||||||||
| arsenic trioxide, radiation therapy | HDAC1 | Direct | 1 | ||||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | HDAC1 | Direct | 1 | ||||||||
| azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab | HDAC1 | Direct | 1 | ||||||||
| belinostat, cisplatin, etoposide | HDAC1 | Direct | 1 | ||||||||
| bevacizumab, temozolomide, vorinostat | HDAC1 | Direct | 1 | ||||||||
| capecitabine, vorinostat, radiotherapy, surgery to remove tumor | HDAC1 | Direct | 1 | ||||||||
| decitabine, gemcitabine | HDAC1 | Direct | 1 | ||||||||
| entinostat, nivolumab, entinostat, nivolumab | HDAC1 | Direct | 1 | ||||||||
| fingolimod | HDAC1 | Direct | 1 | ||||||||
| gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff | HDAC1 | Direct | 1 | ||||||||
| laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat | HDAC1 | Direct | 1 | ||||||||
| pembrolizumab, vorinostat, temozolomide, radiotherapy | HDAC1 | Direct | 1 | ||||||||
| romidepsin | HDAC1 | Direct | yes | 1 | |||||||
| romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule | HDAC1 | Direct | 1 | ||||||||
| romidepsin, laboratory biomarker analysis | HDAC1 | Direct | 1 | ||||||||
| sorafenib tosylate, valproic acid, sildenafil citrate | HDAC1 | Direct | 1 | ||||||||
| standard radiation therapy, standard temozolomide, belinostat | HDAC1 | Direct | 1 | ||||||||
| sx-682, decitabine | HDAC1 | Direct | 1 | ||||||||
| tetrahydrouridine, decitabine | HDAC1 | Direct | 1 | ||||||||
| valproic acid | HDAC1 | Direct | 1 | ||||||||
| valproic acid, bevacizumab, radiation therapy | HDAC1 | Direct | 1 | ||||||||
| valproic acid, simvastatin 20mg, gemcitabine 1000 mg, nab paclitaxel, cisplatin, capecitabine | HDAC1 | Direct | 1 | ||||||||
| vorinostat, bevacizumab | HDAC1 | Direct | 1 | ||||||||
| vorinostat, bevacizumab, irinotecan | HDAC1 | Direct | 1 | ||||||||
| vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis | HDAC1 | Direct | 1 | ||||||||
| vorinostat, conventional surgery | HDAC1 | Direct | 1 | ||||||||
| vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study | HDAC1 | Direct | 1 | ||||||||
| vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration | HDAC1 | Direct | 1 | ||||||||
| vorinostat, therapeutic conventional surgery, bortezomib | HDAC1 | Direct | 1 | ||||||||
| belinostat | HDAC1 | Direct | yes | 0 | |||||||
| panobinostat | HDAC1 | Direct | yes | 0 | |||||||
| panobinostat lactate | HDAC1 | Direct | yes | 0 | |||||||
| vorinostat | HDAC1 | Direct | yes | 0 | |||||||
| olaparib | PARP1 | SSL via PARP1 | yes | 1 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CDK4 | SSL via CDK4 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | ERBB4 | SSL via ERBB4 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | LYN | SSL via LYN | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | SMO | SSL via SMO | 3 | ||||||||
| afatinib | ERBB4 | SSL via ERBB4 | yes | 3 | |||||||
| dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus | MTOR | SSL via MTOR | 3 | ||||||||
| futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan | TOP1 | SSL via TOP1 | 3 | ||||||||
| lurbinectedin, irinotecan | TOP1 | SSL via TOP1 | 3 | ||||||||
| mrtx849, pembrolizumab, cetuximab, afatinib | ERBB4 | SSL via ERBB4 | 3 | ||||||||
| nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone | PPARG | SSL via PPARG | 3 | ||||||||
| abemaciclib | CDK4 | SSL via CDK4 | yes | 2 | |||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | ERBB4 | SSL via ERBB4 | 2 | ||||||||
| alvocidib, paclitaxel | CDK4 | SSL via CDK4 | 2 | ||||||||
| apatinib, irinotecan | TOP1 | SSL via TOP1 | 2 | ||||||||
| asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan | TOP1 | SSL via TOP1 | 2 | ||||||||
| asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine | TOP1 | SSL via TOP1 | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | LYN | SSL via LYN | 2 | ||||||||
| binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib | CDK4 | SSL via CDK4 | 2 | ||||||||
| cetuximab, cisplatin, irinotecan, radiation therapy, surgery | TOP1 | SSL via TOP1 | 2 | ||||||||
| cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study | MTOR | SSL via MTOR | 2 | ||||||||
| eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab | CDK4 | SSL via CDK4 | 2 | ||||||||
| everolimus | MTOR | SSL via MTOR | yes | 2 | |||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study | HDAC2 | SSL via HDAC2 | 2 | ||||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study | HDAC3 | SSL via HDAC3 | 2 | ||||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study | HDAC6 | SSL via HDAC6 | 2 | ||||||||
| inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide | TOP1 | SSL via TOP1 | 2 | ||||||||
| irinotecan, capecitabine | TOP1 | SSL via TOP1 | 2 | ||||||||
| irinotecan, docetaxel | TOP1 | SSL via TOP1 | 2 | ||||||||
| ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab | TOP1 | SSL via TOP1 | 2 | ||||||||
| nintedanib | LYN | SSL via LYN | 2 | ||||||||
| nintedanib, pembrolizumab | LYN | SSL via LYN | 2 | ||||||||
| ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine | TOP2A | SSL via TOP2A | 2 | ||||||||
| palbociclib | CDK4 | SSL via CDK4 | yes | 2 | |||||||
| pembrolizumab, guadecitabine, mocetinostat | HDAC2 | SSL via HDAC2 | 2 | ||||||||
| pembrolizumab, guadecitabine, mocetinostat | HDAC3 | SSL via HDAC3 | 2 | ||||||||
| pembrolizumab, paclitaxel, docetaxel, irinotecan | TOP1 | SSL via TOP1 | 2 | ||||||||
| pembrolizumab, sonidegib | SMO | SSL via SMO | 2 | ||||||||
| pharmacological study, romidepsin | HDAC2 | SSL via HDAC2 | 2 | ||||||||
| pharmacological study, romidepsin | HDAC6 | SSL via HDAC6 | 2 | ||||||||
| rubitecan | TOP1 | SSL via TOP1 | 2 | ||||||||
| sacituzumab govitecan | TOP1 | SSL via TOP1 | yes | 2 | |||||||
| temsirolimus | MTOR | SSL via MTOR | 2 | ||||||||
| temsirolimus, laboratory biomarker analysis | MTOR | SSL via MTOR | 2 | ||||||||
| topotecan | TOP1 | SSL via TOP1 | yes | 2 | |||||||
| trastuzumab deruxtecan | TOP1 | SSL via TOP1 | yes | 2 | |||||||
| 3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| 3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat | HDAC3 | SSL via HDAC3 | 1 | ||||||||
| 3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat | HDAC6 | SSL via HDAC6 | 1 | ||||||||
| 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat | HDAC3 | SSL via HDAC3 | 1 | ||||||||
| 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat | HDAC6 | SSL via HDAC6 | 1 | ||||||||
| 5 fluorouracil, leucovorin, irinotecan, oxaliplatin | TOP1 | SSL via TOP1 | 1 | ||||||||
| 9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan | TOP1 | SSL via TOP1 | 1 | ||||||||
| abemaciclib, abemaciclib | CDK4 | SSL via CDK4 | 1 | ||||||||
| abemaciclib, bevacizumab | CDK4 | SSL via CDK4 | 1 | ||||||||
| abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf | CDK4 | SSL via CDK4 | 1 | ||||||||
| abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf | TOP1 | SSL via TOP1 | 1 |